Up to now, targets studied in AML treatment included CD33 [13], CD123 [11], CD44v6 [16], Lewis Y [17], CLL-1 [12], FLT3 [14], FR beta [18], and CD70 [19, 20]. The gene discussed is CD70; the disease is acute myeloid leukemia.